Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy

This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.

Givosiran: Latex Content

Standard response letter on the latex content of givosiran vial.

Lumasiran: Pregnancy and Lactation

Standard response letter on lumasiran and pregnancy and lactation in the Phase 2 OLE and Phase 3 ILLUMINATE studies.

HELIOS-A: 9-Month Results from the Randomized Treatment Extension Period of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Lumasiran: ILLUMINATE-B Study Overview

Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-B, a study evaluating the efficacy and safety of lumasiran in infants and children less than 6 years old with PH1.

Kidney Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Treated with Long-term Lumasiran

Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with Hereditary Transthyretin Mediated (hATTR) Amyloidosis with a V122I or T60A Variant: A Phase 4 Observational Study

Vutrisiran: Orthostatic Hypotension

Standard response letter on the quantitative effect of vutrisiran on orthostatic hypotension in the HELIOS-A study, assessed using the postural blood pressure component of mNIS+7.

Patisiran: Use in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy

Standard response letter on the use of patisiran in patients with hATTR and mixed phenotype from the APOLLO-B study.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.